retatrutide phase 2 results 2024 2025 Today, we shared new data from two 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide FDA Approval 2025–2026: Phase

You are not imagining things

KFF reports that policymakers and insurers are increasingly evaluating strategies to manage the financial impact of GLP-1 coverage, particularly within Medicare and Medicaid programs where long-term costs could become significant

A plateau is typically defined as no measurable change over 3 to 4 weeks despite consistent adherence to treatment and lifestyle factors

Sun poisoning describes a severe inflammatory reaction to ultraviolet radiation that affects the entire body, not just the skin

A doctor or other trusted healthcare professional can help determine whether a GLP-1 agonist may be beneficial for you, depending on your health concerns and goals

It uses liraglutide, a slightly different GLP-1 medication than semaglutide, and requires daily injections rather than weekly